Skip to main content

Pheochromocytoma Market Analysis, Development Strategies and Forecast to 2025

Market Highlights:
Pheochromocytoma is a catecholamine-secreting rare type of adrenal gland tumor. In this condition, the adrenal gland produces excess amounts of norepinephrine and epinephrine hormones, hence elevating the blood pressure and heart rate.
According to MRFR analysis, the global Pheochromocytoma Market Overview is expected to register a CAGR of 3.84% during the forecast period of 2019 to 2025. The global market was valued at USD 2,814.75 million in 2018.

Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/8556

The global pheochromocytoma market is growing owing to the increasing investment by major companies to develop specific treatment options, high prevalence of pheochromocytoma, and increasing number of clinical trials for drugs for pheochromocytoma. Furthermore, the rapidly changing lifestyle, rising healthcare expenditure, and increasing incidence rate of rare tumors are also expected to fuel the market growth. However, the stringent government regulations, lack of availability of specific drugs and lack of awareness regarding the disease are expected to restrain the growth of the global pheochromocytoma market.
Several market players currently dominate the global pheochromocytoma market. The key players are involved in product launches and acquisitions to strengthen their market positions.
                                                 
Key Players:
  • Pfizer Inc
  • Teva Pharmaceutical Company Limited
  • Zydus Cadila
  • Novartis AG
  • Curium Pharma
  • Jubilant Cadista
  • AstraZeneca
  • Mylan N.V.
  • Apotex Inc
  • Reddy’s Laboratories Ltd
  • Lupin
  • Glenmark Pharmaceuticals Limited
  • Exelixis
  • Progenics Pharmaceuticals
  • Oncoceutics
  • FUJIFILM Holdings Corporation
  • Advanced Accelerator Applications

Segmentation
  • The global pheochromocytoma market has been segmented based on treatment type and end user.
  • The global pheochromocytoma market has been segmented, on the basis of treatment type, into alpha-blockers, beta-blockers, surgery, radionuclide treatment, and others. The surgery segment is expected to hold the largest market share as it is the most preferred treatment option for pheochromocytoma. The radionuclide treatment is expected to grow at the fastest CAGR owing to increasing number of applications of radiopharmaceuticals in the treatment of various diseases.
  • The market based on end user has been segmented into hospitals & clinics, research & academic institutes, and others. Hospitals and clinics are the first point of treatment for any disease; hence it is expected to hold the largest market share. Research & academic institutes are expected to grow at the fastest CAGR owing to increasing research & development activities for better treatment options for pheochromocytoma..

Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of pheochromocytoma. The pheochromocytoma market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European pheochromocytoma market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The pheochromocytoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool suffering from rare tumors, the market in Asia-Pacific is expected to be the fastest-growing. The pheochromocytoma market in the Middle East & Africa has been divided into the Middle East and Africa.


NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
Labels:

Comments

Post a Comment

Popular posts from this blog

Covid 19 Analysis on Respiratory Therapeutic Devices Market Analysis and Forecast to 2023

Market Overview: The Global Respiratory Therapeutic Devices Market is predicted to scale to new heights and expand at a CAGR of 10.8% over the forecast period of 2017-2023, asserts Market Research Future (MRFR) in an in-depth study.                   The growth of the Global Covid 19 Analysis on Respiratory Therapeutic Devices Market Analysis   is primarily led by the recent surge in the incidence of chronic respiratory diseases such as asthma, COPD, and sleep disorder breathing. As per the estimates of the World Health Organization (WHO), approximately 235 Mn people suffered from asthma in 2017 across the globe. The growing burden of chronic respiratory diseases (CRDs) induces strong demand for respiratory therapeutic devices within the market. Moreover, with the increase in the global aging population, there is a greater need for respiratory therapeutic devices.     ...
Post a Comment
Read more

Antibody Drug Conjugate Market is Presumed to Grow at a Reliable CAGR of 19% During Forecast to 2023

Antibody Drug Conjugate Market Analysis: Various factors are adding to the global antibody drug conjugate market share. These factors, as per the new MRFR report, include advances in medical technology, rising cases of cancer, growing obese population, and increasing aging population. Additional factors adding market growth include increasing collaborations between biotechnology companies, biopharmaceuticals, and research institutes, rising R&D on oncology diseases, increasing research on advanced drug discoveries, rising number of research on antibody therapies, and preclinical research. The global Antibody Drug Conjugate Market Share is likely to grow at a 19% CAGR between 2017- 2023 , reveals the new Market Research Future (MRFR) report. Antibody drug conjugates are new-age therapeutic agents that have three parts- a chemical linker to attach cytotoxic agents to antibodies, cytotoxic agents for killing target cancer cells, and specific antibodies for binding. Lymphoma, mult...
Post a Comment
Read more

Desalting and Buffer Exchange Market is Growing at a Healthy CAGR of 10.5% During Forecast to 2023

Market Highlights: The Global Desalting and Buffer Exchange Market is anticipated to have held a market value of USD 615.20 million in the year 2017 and is expected to grow at a CAGR of 10.5% during the forecast period. Desalting and buffer exchange play a key role in biotechnological companies. Buffer exchange is used to place a protein solution into a more suitable buffer before applications such as electrophoresis, ion exchange, affinity chromatography among others. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/6633 Buffer exchange is the term used when one set of buffer salts in a sample is exchanged by another more appropriate buffer set. The rising demand for monoclonal antibodies, growing research and development expenditure by the biopharmaceutical companies, and rising focus on proteomic and genomic research is anticipated to boost the growth of the market over the forecast period. However, the dearth of skilled professionals is excepted to ...
Post a Comment
Read more